Early Identification of Patients at Risk of Cabazitaxel-induced Severe Neutropenia

Bram C Agema*, Stefan A J Buck, Mano Viskil, Khrystany T Isebia, Micha J de Neijs, Sebastiaan D T Sassen, Birgit C P Koch, Markus Joerger, Ronald de Wit, Stijn L W Koolen, Ron H J Mathijssen

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

1 Citation (Scopus)
6 Downloads (Pure)

Abstract

BACKGROUND: Cabazitaxel frequently causes severe neutropenia. A higher cabazitaxel systemic exposure is related to a lower nadir absolute neutrophil count (ANC).

OBJECTIVE: To describe the effect of cabazitaxel systemic exposure on ANC by a population pharmacokinetic/pharmacodynamic (POP-PK/PD) model, and to identify patients at risk of severe neutropenia early in their treatment course using a PK threshold.

DESIGN, SETTING, AND PARTICIPANTS: Data from five clinical studies were pooled to develop a POP-PK/PD model using NONMEM, linking both patient characteristics and cabazitaxel systemic exposure directly to ANC.

OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: A PK threshold, predictive of severe neutropenia (grade ≥3), was determined using a receiver operating characteristic curve.

RESULTS AND LIMITATIONS: Ninety-six patients were included with a total of 1726 PK samples and 1081 ANCs. The POP-PK/PD model described both cabazitaxel PK and ANC accurately. A cabazitaxel plasma concentration of >4.96 ng/ml at 6 h after the start of infusion was found to be predictive of severe neutropenia, with a sensitivity of 76% and a specificity of 65%.

CONCLUSIONS: Early cabazitaxel plasma levels are predictive of severe neutropenia. Implementation of the proposed PK threshold results in early identification of almost 76% of all severe neutropenias. If prospectively validated, patients at risk could benefit from prophylactic administration of granulocyte colony stimulating factors, preventing severe neutropenia in an early phase of treatment. Implementation of this threshold permits a less restricted use of the 25 mg/m2 dose, potentially increasing the therapeutic benefit.

PATIENT SUMMARY: Treatment with cabazitaxel chemotherapy often causes neutropenia, leading to susceptibility to infections, which might be life threatening. We found that a systemic cabazitaxel concentration above 4.96 ng/ml 6 h after the start of infusion is predictive of the occurrence of severe neutropenia. Measurement of systemic cabazitaxel levels provides clinicians with the opportunity to prophylactically stimulate neutrophil growth.

Original languageEnglish
Pages (from-to)786-793
Number of pages8
JournalEuropean urology oncology
Volume7
Issue number4
Early online date3 Nov 2023
DOIs
Publication statusPublished - 1 Aug 2024

Bibliographical note

Publisher Copyright:
Copyright © 2023 The Author(s). Published by Elsevier B.V. All rights reserved.

Fingerprint

Dive into the research topics of 'Early Identification of Patients at Risk of Cabazitaxel-induced Severe Neutropenia'. Together they form a unique fingerprint.

Cite this